A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy

May Cho, Jun Gong, Paul Frankel, Timothy W. Synold, Dean Lim, Vincent Chung, Joseph Chao, Daneng Li, Yuan Chen, Stephen Sentovich, Kurt Melstrom, Gagandeep Singh, Eloise Luevanos, Marwan Fakih

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: This was a first in-human, open-label, dose-escalation phase I study conducted to evaluate the maximum tolerated dose (MTD), safety, and efficacy of the combination of oral binimetinib and FOLFOX. Materials and Methods: Patients with metastatic colorectal cancer (mCRC) who progressed on prior standard therapies received twice daily binimetinib continuously or intermittently with FOLFOX. Dose-limiting toxicities (DLTs) were assessed in the first 2 cycles of study treatment. Pharmacokinetic (PK) analysis of 5-FU and oxaliplatin was performed at the MTD in an expanded 6 patient cohort. Results: Twenty-six patients were enrolled and assessed for safety. In the doseescalation phase, no DLTs were noted in all binimetinib dosing schedules and the MTD of binimetinib in with FOLFOX was 45 mg orally twice daily. There were no significant differences in the PKs of 5-FU or oxaliplatin with or without binimetinib. Continuous dosing of binimetinib produced SD at 2 months in 9 of 13 evaluable patients and a median PFS of 3.5 months. Nine of 10 patients had PD at 2 months on the intermittent arm. Conclusions: Oral binimetinib and FOLFOX has a manageable toxicity profile and showed some evidence of antitumor activity in heavily pretreated mCRC patients.

Original languageEnglish (US)
Pages (from-to)79750-79760
Number of pages11
JournalOncotarget
Volume8
Issue number45
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Clinical Trials, Phase I
Colorectal Neoplasms
oxaliplatin
Maximum Tolerated Dose
Fluorouracil
Therapeutics
Safety
MEK162
Appointments and Schedules
Pharmacokinetics

Keywords

  • Binimetinib
  • FOLFOX
  • MEK inhibitor
  • Metastatic colorectal cancer
  • Refractory disease

ASJC Scopus subject areas

  • Oncology

Cite this

A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy. / Cho, May; Gong, Jun; Frankel, Paul; Synold, Timothy W.; Lim, Dean; Chung, Vincent; Chao, Joseph; Li, Daneng; Chen, Yuan; Sentovich, Stephen; Melstrom, Kurt; Singh, Gagandeep; Luevanos, Eloise; Fakih, Marwan.

In: Oncotarget, Vol. 8, No. 45, 01.01.2017, p. 79750-79760.

Research output: Contribution to journalArticle

Cho, M, Gong, J, Frankel, P, Synold, TW, Lim, D, Chung, V, Chao, J, Li, D, Chen, Y, Sentovich, S, Melstrom, K, Singh, G, Luevanos, E & Fakih, M 2017, 'A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy', Oncotarget, vol. 8, no. 45, pp. 79750-79760. https://doi.org/10.18632/oncotarget.19336
Cho, May ; Gong, Jun ; Frankel, Paul ; Synold, Timothy W. ; Lim, Dean ; Chung, Vincent ; Chao, Joseph ; Li, Daneng ; Chen, Yuan ; Sentovich, Stephen ; Melstrom, Kurt ; Singh, Gagandeep ; Luevanos, Eloise ; Fakih, Marwan. / A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy. In: Oncotarget. 2017 ; Vol. 8, No. 45. pp. 79750-79760.
@article{20615b1c9ba6476fb837a6a1bd54e344,
title = "A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy",
abstract = "Background: This was a first in-human, open-label, dose-escalation phase I study conducted to evaluate the maximum tolerated dose (MTD), safety, and efficacy of the combination of oral binimetinib and FOLFOX. Materials and Methods: Patients with metastatic colorectal cancer (mCRC) who progressed on prior standard therapies received twice daily binimetinib continuously or intermittently with FOLFOX. Dose-limiting toxicities (DLTs) were assessed in the first 2 cycles of study treatment. Pharmacokinetic (PK) analysis of 5-FU and oxaliplatin was performed at the MTD in an expanded 6 patient cohort. Results: Twenty-six patients were enrolled and assessed for safety. In the doseescalation phase, no DLTs were noted in all binimetinib dosing schedules and the MTD of binimetinib in with FOLFOX was 45 mg orally twice daily. There were no significant differences in the PKs of 5-FU or oxaliplatin with or without binimetinib. Continuous dosing of binimetinib produced SD at 2 months in 9 of 13 evaluable patients and a median PFS of 3.5 months. Nine of 10 patients had PD at 2 months on the intermittent arm. Conclusions: Oral binimetinib and FOLFOX has a manageable toxicity profile and showed some evidence of antitumor activity in heavily pretreated mCRC patients.",
keywords = "Binimetinib, FOLFOX, MEK inhibitor, Metastatic colorectal cancer, Refractory disease",
author = "May Cho and Jun Gong and Paul Frankel and Synold, {Timothy W.} and Dean Lim and Vincent Chung and Joseph Chao and Daneng Li and Yuan Chen and Stephen Sentovich and Kurt Melstrom and Gagandeep Singh and Eloise Luevanos and Marwan Fakih",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.19336",
language = "English (US)",
volume = "8",
pages = "79750--79760",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "45",

}

TY - JOUR

T1 - A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy

AU - Cho, May

AU - Gong, Jun

AU - Frankel, Paul

AU - Synold, Timothy W.

AU - Lim, Dean

AU - Chung, Vincent

AU - Chao, Joseph

AU - Li, Daneng

AU - Chen, Yuan

AU - Sentovich, Stephen

AU - Melstrom, Kurt

AU - Singh, Gagandeep

AU - Luevanos, Eloise

AU - Fakih, Marwan

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: This was a first in-human, open-label, dose-escalation phase I study conducted to evaluate the maximum tolerated dose (MTD), safety, and efficacy of the combination of oral binimetinib and FOLFOX. Materials and Methods: Patients with metastatic colorectal cancer (mCRC) who progressed on prior standard therapies received twice daily binimetinib continuously or intermittently with FOLFOX. Dose-limiting toxicities (DLTs) were assessed in the first 2 cycles of study treatment. Pharmacokinetic (PK) analysis of 5-FU and oxaliplatin was performed at the MTD in an expanded 6 patient cohort. Results: Twenty-six patients were enrolled and assessed for safety. In the doseescalation phase, no DLTs were noted in all binimetinib dosing schedules and the MTD of binimetinib in with FOLFOX was 45 mg orally twice daily. There were no significant differences in the PKs of 5-FU or oxaliplatin with or without binimetinib. Continuous dosing of binimetinib produced SD at 2 months in 9 of 13 evaluable patients and a median PFS of 3.5 months. Nine of 10 patients had PD at 2 months on the intermittent arm. Conclusions: Oral binimetinib and FOLFOX has a manageable toxicity profile and showed some evidence of antitumor activity in heavily pretreated mCRC patients.

AB - Background: This was a first in-human, open-label, dose-escalation phase I study conducted to evaluate the maximum tolerated dose (MTD), safety, and efficacy of the combination of oral binimetinib and FOLFOX. Materials and Methods: Patients with metastatic colorectal cancer (mCRC) who progressed on prior standard therapies received twice daily binimetinib continuously or intermittently with FOLFOX. Dose-limiting toxicities (DLTs) were assessed in the first 2 cycles of study treatment. Pharmacokinetic (PK) analysis of 5-FU and oxaliplatin was performed at the MTD in an expanded 6 patient cohort. Results: Twenty-six patients were enrolled and assessed for safety. In the doseescalation phase, no DLTs were noted in all binimetinib dosing schedules and the MTD of binimetinib in with FOLFOX was 45 mg orally twice daily. There were no significant differences in the PKs of 5-FU or oxaliplatin with or without binimetinib. Continuous dosing of binimetinib produced SD at 2 months in 9 of 13 evaluable patients and a median PFS of 3.5 months. Nine of 10 patients had PD at 2 months on the intermittent arm. Conclusions: Oral binimetinib and FOLFOX has a manageable toxicity profile and showed some evidence of antitumor activity in heavily pretreated mCRC patients.

KW - Binimetinib

KW - FOLFOX

KW - MEK inhibitor

KW - Metastatic colorectal cancer

KW - Refractory disease

UR - http://www.scopus.com/inward/record.url?scp=85030481753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030481753&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.19336

DO - 10.18632/oncotarget.19336

M3 - Article

AN - SCOPUS:85030481753

VL - 8

SP - 79750

EP - 79760

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 45

ER -